A Changing AML Landscape: Adapting Target-Specific Treatments to Individual Patients

For 4 decades, no new agents had been permanently approved for the management of acute myeloid leukemia (AML) in both the newly diagnosed and relapsed/refractory settings. That has changed dramatically in the last 2 years with the approval of 8 new agents and several more in clinical development. This initiative includes activities that provide insight into advances in molecular alterations—FLT3, CD33, IDH-1/2, BCL-2, and others—that may trigger AML in individual patients, and the safety and efficacy of target-specific agents, alone and in combination with other therapies, that inhibit those genetic alterations and have had a significant impact on overall survival.

Intended Audience

Hematologists-oncologists, nurse practitioners (NPs), physician assistants (PAs), oncology nurses, and advanced practitioners in oncology and specialty pharmacists (includes hospital pharmacists and pharmacy specialties such as associate directors, pharmacy directors, clinical coordinators, clinical pharmacist generalists, and clinical pharmacist specialists)

Educational Objectives

For Physicians, Nurse Practitioners, and Physician Assistants:

  • Describe the molecular pathways of FLT3, CD33, B-cell lymphoma-2 (BCL-2), and isocitrate dehydrogenase (IDH)-2 and the rationale behind targeted inhibition in acute myeloid leukemia (AML)
  • Recognize FLT3 mutation–positive (FLT3+) relapsed or refractory AML patients
  • Explain the efficacy and safety of new therapies for FLT3+ AML patients
  • Evaluate patient characteristics and preferences to develop personalized treatment plans for patients with AML to improve prognosis and outcomes

For Nurses:

  • Recognize FLT3+ relapsed or refractory AML
  • Explain the efficacy and safety of new therapies for FLT3+ AML patients
  • Counsel patients and caregivers regarding the efficacy and safety of FLT3-specific therapies throughout the course of their treatment plans

For Pharmacists:

  • Recognize FLT3+ relapsed or refractory AML
  • Explain the efficacy and safety of new therapies for FLT3+ AML patients
  • Describe the mechanisms of action of new therapies for FLT3+ patients
  • Counsel patients with FLT3+ AML regarding drug-drug interactions and contraindications for specific targeted therapies

FLT3+ AML Patients: Assessing the Evidence for New Targeted Treatments

Release: January 22, 2019
Expiration: January 22, 2020

CME|CPE|CE 0.70-0.75 Credit

Viewpoints in AML: Taking Progress Forward

Release: March 4, 2019
Expiration: March 4, 2020

CME|CPE|CE 1.00 Credit


Rami Komrokji, MD
Senior Member
Section Head, Leukemia and MDS
Vice Chair, Malignant Hematology
H. Lee Moffitt Cancer Center
Professor of Oncologist Sciences
University of South Florida
Tampa, FL

Eytan M. Stein, MD
Hematologic Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Co-provided by


These activities are supported by an educational grant from
Astellas Pharma US, Inc.

Medical Minutes

View additional expert commentary on specific concerns in the management of AML below. (Both are noncertified and are for educational purposes only.)

Oral Targeted AML Therapies:
Profound At-Home Convenience
for Older Patients

A Paradigm Shift in AML:
The Delivery of Care in the
Outpatient Setting